XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further developed i | XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further developed into novel therapeutics—and Eli Lilly wants a piece of the AI drug development pie.
